Grifols, S.A. (GRFS)
NASDAQ: GRFS · Real-Time Price · USD
8.67
+0.31 (3.71%)
Nov 25, 2025, 4:00 PM EST - Market closed
Grifols Revenue
Grifols had revenue of 1.87B EUR in the quarter ending September 30, 2025, with 4.04% growth. This brings the company's revenue in the last twelve months to 7.52B, up 7.31% year-over-year. In the year 2024, Grifols had annual revenue of 7.21B with 9.41% growth.
Revenue (ttm)
7.52B EUR
Revenue Growth
+7.31%
P/S Ratio
0.82
Revenue / Employee
316,727 EUR
Employees
23,737
Market Cap
7.27B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.21B | 620.41M | 9.41% |
| Dec 31, 2023 | 6.59B | 528.01M | 8.71% |
| Jan 1, 2023 | 6.06B | 1.13B | 22.92% |
| Dec 31, 2021 | 4.93B | -406.92M | -7.62% |
| Dec 31, 2020 | 5.34B | 241.35M | 4.73% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GRFS News
- 20 days ago - Grifols, S.A. (GIKLY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Top Biotech Stocks Riding The Rally - Seeking Alpha
- 26 days ago - 4 Best Value And Growth Stocks (Yes, They Can Coexist) - Seeking Alpha
- 6 weeks ago - Spanish court summons Gotham City founder in Grifols share price probe - Reuters
- 7 weeks ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 7 weeks ago - Grifols: Significant Upside Likely Materializing - Seeking Alpha
- 6 months ago - XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology - GlobeNewsWire
- 6 months ago - Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting - Business Wire